Applications of rituximab in the treatment of renal diseases
As a monoclonal antibody targeting CD20 on the surface of B lymphocytes,rituximab causes the dissolution of B cells through immune action.Plasma cells lack CD20 antigen.Rituximab is both effective and safe for lupus nephritis,ANCA-associated vasculitis,refractory minimal change nephropathy,focal seg...
Saved in:
| Main Authors: | Liu Zi, Hu Zhi-juan |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Department of Journal of Clinical Nephrology
2021-01-01
|
| Series: | Linchuang shenzangbing zazhi |
| Subjects: | |
| Online Access: | http://www.lcszb.com/thesisDetails?columnId=57905367&Fpath=home&index=0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical features and outcomes of patients with antineutrophil cytoplasmic antibody-positive systemic lupus erythematosus
by: Ying Wang, et al.
Published: (2023-12-01) -
USE OF RITUXIMAB IN PATIENTS WITH LUPUS NEPHRITIS
by: Anna Vasilyevna Torgashina, et al.
Published: (2010-08-01) -
“Fleshy” Skin Cellulitis: A Triggering Factor for ANCA Associated Vasculitis
by: Sim Chun Yang, et al.
Published: (2020-02-01) -
Obinutuzumab and Ofatumumab are More Effective Than Rituximab in the Treatment of Membranous Nephropathy Patients With Anti-Rituximab Antibodies
by: Maxime Teisseyre, et al.
Published: (2025-03-01) -
RUSSIAN EXPERIENCE WITH USING MONOCLONAL ANTIBODIES TO B-LYMPHOCYTES (RITUXIMAB) IN SYSTEMIC VASCULITIDES ASSOCIATED WITH NEUTROPHIL CYTOPLASMIC ANTIBODIES (PRELIMINARY RESULTS OF THE RUSSIAN REGISTER NORMA)
by: T. V. Beketova, et al.
Published: (2014-06-01)